All-trans retinoic acid (ATRA) significantly improves the survival of patients with acute promyelocytic leukemia (APL) by inducing granulocytic differentiation of leukemia cells. Since an activation of the transcription factor NF-jB occurs during ATRA-induced maturation of APL cells, a mechanistic link between these two processes was investigated. Using an in vitro model for APL, we report that ectopic overexpression of a repressor of NF-jB activation did not affect granulocytic differentiation. Importantly, NF-jB inhibition markedly resulted in a decreased viability of the differentiated cells, which correlated with increased apoptosis. Apoptosis was accompanied by a sustained activation of the c-Jun N-terminal kinase (JNK). Inhibition of JNK by the specific inhibitor SP600125 or by transfection of a dominant-negative mutant of JNK1 reduced the percentage of apoptotic cells, thus showing that JNK activation constitutes a death signal. Furthermore, impairment of NF-jB activation resulted in increased levels of reactive oxygen species (ROS) upon ATRA treatment. ROS accumulation was suppressed by the antioxidant butylated hydroxyanisol, which also abolished ATRA-induced JNK activation and apoptosis. Altogether, our results demonstrate an antiapoptotic effect of NF-jB activation during ATRA-induced differentiation of NB4 cells and identify repression of ROS-mediated JNK activation as a mechanism for this effect. Our observations also suggest that NF-jB signalling may contribute to an accumulation of mature APL cells and participate in the development of ATRA syndrome. Oncogene (2005) 24, 7145-7155.
Introduction
The most frequent form of acute promyelocytic leukemia (APL) is characterized by the t(15;17) chromosomal translocation in promyelocytic leukemic blasts. The translocation product PML-retinoic acid receptor (RAR)a, by alteration of both PML and RAR functions, is thought to be responsible for increased survival and altered maturation of promyelocytes (de The´et al., 1991; Slack and Gallagher, 1999; Puccetti and Ruthardt, 2004) . Administration of pharmacological doses of all-trans retinoic acid (ATRA) to APL patients restores differentiation of leukemic cells, leading to a temporary remission of the disease (Huang et al., 1988; Chomienne et al., 1996; de The´and Chelbi-Alix, 2001 ).
ATRA effects at the level of gene transcription are mediated through nuclear RARs and rexinoid receptors (RXRs) (Chambon, 1996) . In addition to inducing transcription, liganted receptors can also affect the activity of other transcription factors. In particular, retinoid receptors are known to repress growthstimulating transcription factor AP1 (Jun/Fos) (Nicholson et al., 1990) . Of note, retinoids can also modulate the activity of the transcription factor NF-kB. Indeed, an activation of this factor has been observed during RARa agonist-or ATRA-induced granulocytic differentiation of NB4 cells Benoit et al., 2001) , a cell line which offers an in vitro model to study APL (Lanotte et al., 1991) . ATRA was also shown to potentiate TNFa-induced NF-kB activation (Witcher et al., 2003) . Therefore, identification of the functional consequences of such either ATRA-activated or -repressed pathways could help to devise beneficial combination therapies improving its efficiency.
The inducible transcription factor NF-kB plays a critical role in the response of cells to their environment. In most cells, NF-kB proteins are sequestered in the cytoplasm bound to the specific IkB inhibitory proteins, of which IkBa is the paradigm. Many signals turn on the classical pathway of NF-kB activation. In this pathway, the b subunit of the IkB kinase (IKK) complex phosphorylates IkBa on two N-terminal conserved serines , leading to its polyubiquitination and subsequent proteasomal degradation (Hayden and Ghosh, 2004) . Recently, an alternative proteasome-independent and calpain-dependent mechanism of proteolytic IkBa degradation has also been described (Miyamoto et al., 1998; Han et al., 1999; Pianetti et al., 2001; Kouba et al., 2001; Berry et al., 2002; Waris et al., 2003) . Once liberated from IkBa, NF-kB dimers translocate to the nucleus, where they regulate transcription of target genes. NF-kB proteins are key regulators of numerous biological processes.
NF-kB activity can affect cell proliferation by controlling expression of cell cycle regulators (Chen et al., 2001) . NF-kB pathway is also involved in the regulation of differentiation in many different systems, including mammalian skin, neuronal cells, osteoclasts, myoblasts, and the innate and adaptive immune systems (Iotsova et al., 1997; Bell et al., 2003; Nickols et al., 2003; Bonizzi and Karin, 2004) . In addition, analysis of NF-kBdeficient mice and cells identified this transcription factor as a major determinant of cell survival (Karin and Lin, 2002; Kucharczak et al., 2003) and sensitivity of cancers to chemotherapy (Orlowski and Baldwin, 2002) .
In the present study, we investigated the role of NF-kB during the course of ATRA-induced maturation of NB4 cells. We report that NF-kB activation is not essential to granulocytic differentiation of these cells, but constitutes a survival signal during this process. We also identified NF-kB-mediated repression of reactive oxygen species (ROS)-induced c-Jun N-terminal kinase (JNK) activation as a mechanism of its antiapoptotic effect.
Results

Generation of transgenic NB4 cells expressing a repressor of NF-kB activation
To study the functional consequences of NF-kB activation during ATRA-induced granulocytic differentiation of NB4 cells, stable transformants expressing the super repressor form of IkBa, IkBa (A32/36), were generated. The IkBa (A32/36) contains serine-to-alanine mutations at residues 32 and 36, which confer resistance to signal-induced phosphorylation and subsequent proteasome-mediated degradation. The mutant protein still binds to NF-kB, sequesters it in the cytoplasm, and thus acts like a constitutive repressor of its activation (Traenckner et al., 1995) .
The expression of the super repressor in the stable transformants and its resistance to TNFa-induced degradation were investigated by Western blot analyses. For this purpose, cellular extracts were prepared from three cell lines: NB4 cells, NB4 cells transfected with the Migr-eGFP vector (NB4/GFP cells), and NB4 cells transfected with the IkBa(A32/36)-encoding Migr-eGFP vector (NB4/GFP-MAD cells) (Figure 1a) . The fact that the mutated IkBa cDNA we used encodes a protein which migrates slower than the wild type (Cai et al., 1997; Javelaud et al., 2000) allowed us to compare expression of both forms after treatment of cells with TNFa. In the three cell lines, the wild-type IkBa was present, which, as expected, was degraded after a 15 min treatment with TNFa. A band corresponding to mutated IkBa was seen in the NB4/GFP-MAD cells only, but was not affected by TNFa treatment. Of note, the expression of IkBa (A32/36) had no effect on cell viability and proliferation rate in the absence of treatment (not shown). The functional consequences of IkBa (A32/36) expression were verified by comparing TNFa-induced NF-kB activation in NB4/GFP cells and in NB4/GFP-MAD cells. Induction of NF-kB binding activity by TNFa was strongly reduced in NB4/GFP-MAD cells as compared to that observed in NB4/GFP cells (Figure 1b) .
We and others have previously reported that NF-kB is activated during RARa agonist-or ATRA-induced maturation of NB4 cells Benoit et al., 2001 ). Here we show that, like its effect on TNFainduced NF-kB activation, overexpression of IkBa(A32/ 36) inhibits activation of NF-kB by ATRA (Figure 1c) . Therefore, the NB4/GFP-MAD cells constitute a valuable tool to study the role of NF-kB activation during ATRA-induced differentiation of NB4 cells.
Inhibition of calpain but not of IKK activity impairs ATRA-induced degradation of IkBa
To get insight into the molecular mechanism of ATRAinduced NF-kB activation, expression of IkBa and of its mutant form were measured at different times after addition of ATRA. A time-dependent decrease in both wild-type IkBa and mutant IkBa(A32/36) was observed, indicating that this degradation did not require phosphorylation of IkBa on serines 32 and 36 (Figure 2a ). EMSA analysis of ATRA-induced NF-kB activation shows that the kinetics of this activation (Figure 2b ) are (c) At the times indicated, nuclear extracts were prepared and analysed by EMSA for NF-kB activity similar to those of IkBa degradation, suggesting a cause-effect relationship between the two events. From this experiment, we can also conclude that the inhibitory effect of IkBa(A32/36) on ATRA-induced NF-kB activation is not linked to its mutation on the two serines, but is only the consequence of its overexpression. In accordance with this observation, the antibody that specifically recognizes the phosphorylated form (on serines 32 and 36) of IkBa did not detect such a form in ATRA-treated cells, although this form of IkBa was present in cells treated with TNFa for 15 min (Figure 2c ).
To further establish that ATRA-induced IkBa degradation occurs independently of the IKK-mediated IkBa phosphorylation, three inhibitors of this phosphorylation were used: Bay 11-7082 (2.5 mM), NBD, a NEMObinding domain-binding peptide (50 mM), and an IKK inhibitor peptide (15 mM). Western blot analysis of IkBa expression after 3 days of treatment with ATRA showed that these inhibitors did not impede IkBa degradation (Figure 2d ).
The possible implication of calpain in ATRA-induced IkBa degradation was tested by using a calpain inhibitor, PD150606, which blocks its calcium-binding site (Wang et al., 1996) . Addition of this inhibitor to ATRA-treated cells resulted in an increased level of IkBa expression as compared to its expression in cells treated with ATRA alone (Figure 2d and e), while the inactive analogue, PD145305, had no effect (Figure 2e ). Inhibition of calpain activity with PD150606 also resulted in inhibition of ATRA-induced IkBa(A32/36) degradation, arguing strongly in favor of a role of calpain in the degradation of both the wild-type and the mutant IkBa protein (Figure 2e ). In accordance with its inhibitory effect on IkBa degradation, ATRA-induced NF-kB activation was specifically inhibited by PD150606, as assessed by EMSA analysis (Figure 2f ).
The repressor of NF-kB activation does not impair granulocytic maturation
The transcriptional activity of NF-kB is essential for the differentiation of several cell types. Here we investigated whether ATRA-induced granulocytic differentiation would be impaired in NB4/GFP-MAD cells carrying the repressor of NF-kB activation. For this purpose, several features of ATRA-induced NB4 cell maturation were compared in NB4/GFP and NB4/GFP-MAD cells. As shown previously, ATRA treatment resulted in a reduction of cell proliferation, which was comparable in both cell lines (Figure 3a ). Maturation was assessed by nitroblue tetrazolium (NBT) reduction analysis, expression of cell surface CD11c, and morphological changes. As shown in Figure 3b and c, the kinetics of increase of NBT-positive cells and of CD11c expression were not modified by the presence of the repressor. Furthermore, MGG-stained cytosmears revealed that these two cell lines did not differ with respect to the morphological features of granulocytic maturation after ATRA treatment (similar increased proportion of cells with lobed nuclei, reduced nucleus/cytoplasm ratio, and less basophilic cytoplasm) ( Figure 3d ). We therefore conclude that NF-kB activation is not essential to granulocytic differentiation of NB4 cells.
NF-kB activation initiates a survival signaling during ATRA-induced maturation of NB4 cells
The previously described antiapoptotic effect of NF-kB (Kucharczak et al., 2003) prompted us to explore whether inhibition of ATRA-induced NF-kB activation would have an incidence on the viability of the differentiated NB4 cells. As seen in Figure 4a , the viability of the NB4/GFP-MAD cells decreased progressively during ATRA treatment as compared to that of identically treated NB4/GFP cells. Concomitant with the decreasing viability of NB4/GFP-MAD cells, the number of cells with characteristic features of apoptosis (i.e. condensed and fragmented nuclei, nucleosomal DNA fragmentation) increased, as shown by Hoechst dye-stained nuclei morphology (Figure 4b ) and DNA laddering (Figure 4c) .
The dissipation of the mitochondrial membrane potential (DCm) is an early event of the intrinsic pathway leading to apoptosis (Green and Reed, 1998) . To get further insight into the mechanisms of ATRA-induced apoptosis, cells were labeled with CMXRos, a red fluorescent cationic marker that accumulates in the mitochondria under the influence of DCm. As shown in Figure 4d , a drop in DCm was observed only in the population of ATRA-treated NB4/GFP-MAD cells, thus showing the participation of mitochondria in the apoptotic process. Accordingly, caspase-9 activation was also observed in these cells (Figure 4e, upper) and apoptosis was inhibited by the pan-caspase inhibitor Z-VAD and the specific caspase-9 inhibitor Z-LEHD (Figure 4e, bottom) .
Since signals triggered by death receptors can accelerate or suppress neutrophil apoptosis (Akgul and Edwards, 2003), we also investigated whether an increased expression of such receptors could also contribute to the higher sensitivity of NB4/GFP-MAD cells to ATRA-induced apoptosis. As shown in , no significant changes in Fas, TNFa, or Trail receptors (DR4 and DR5) surface expression was seen between control or ATRA-treated NB4/GFP and NB4/ GFP-MAD cells. However, one cannot eliminate a role of death receptor ligands in the apoptotic process, since we observed that IkBaA32/36 expression increased the sensitivity of the differentiated cells to Fas ligand (FasL), Trail, and TNFa (Figure 4g ).
Repression of JNK activation participates in the antiapoptotic effect of NF-kB in ATRA-treated NB4 cells
The antiapoptotic effect of NF-kB has been shown to result from its ability to activate transcription of mRNAs encoding antiapoptotic proteins (Kucharczak et al., 2003) . An increased expression of several of these mRNAs (cIAP1, cIAP2, XIAP, A1/Bfl1, and Bcl-xl) . Z-LEHD-fmk (10 mM) or Z-VAD-fmk (10 mM) were added at day 4 of ATRA treatment and the percentage of apoptotic cells was measured at day 6 (bottom). (f) Expression of death receptors was measured at day 4 of ATRA treatment. Data were normalized to control NB4/GFP cells. (g) At day 3 of ATRA treatment, FasL (10 ng/ml), TRAIL (25 ng/ml), or TNFa (0.2 ng/ml) was added. The percentage of cells carrying an apoptotic nuclei was evaluated 24 h later after treatment of NB4 cells with ATRA has been reported . To get further insight into the mechanism of the antiapoptotic effect of NF-kB during this treatment, we examined the expression of these NF-kB-regulated antiapoptotic candidates at the protein level. As shown in Figure 5a , no ATRA-induced upregulation of these proteins could be demonstrated. The two anti-A1/Bfl-1 antibodies we used did not allow us to detect expression of this 20 kDa protein, either in control or ATRA-treated cells. Levels of cIAP2 and Bclxl remained unchanged, those of cIAP1, XIAP, and Bcl2 decreased, and similar profiles were obtained for both cell lines. It is thus unlikely that these proteins are implicated in the NF-kB-mediated protection of ATRAtreated NB4 cells from cell death.
Recent studies have shown that repression of JNK activation is a novel mechanism for the control of TNFinduced apoptosis by NF-kB (De Smaele et al., 2001; Javelaud and Besanc¸on, 2001; Tang et al., 2001; Pham et al., 2004) . We therefore investigated the consequence of ATRA treatment on JNK activation and possible modulation of such activation by the repressor of NF-kB. Cells were treated for different times with ATRA, and JNK activation was determined by Western blot analysis using antibodies that specifically recognized phosphorylated forms of this kinase. Whereas in both cell lines ATRA treatment did not modify JNK expression, it resulted in a strong increase of JNK activation in NB4/GFP-MAD cells as compared to NB4/GFP cells (Figure 5a ). The kinetics of JNK activation were similar to those of the apoptotic process, as they increased between days 4 and 6 of treatment. It has been reported that JNK can either promote or inhibit apoptosis depending on cell type and death stimulus (Lin and Dibling, 2002) . To evaluate the consequence of JNK activation, the JNK inhibitor SP600125 was used. As shown in Figure 5b and c, SP600125 partially reversed the decreased viability of ATRA-treated NB4/GFP-MAD cells. To further establish the role of JNK activation in the apoptotic process, NB4/GFP-MAD cells were transiently transfected with an empty pcDNA vector or a vector encoding a mutant JNK1 (JNKDN). This mutant is an inactive enzyme mutated at Thr183 and Tyr185, which acts as a dominant-negative form of JNK1 (Xia et al., 1995) . As a control, transfection of wild-type JNK1 (JNKWT) was performed. As shown in Figure 5d , expression of JNKDN reduced apoptosis of ATRA-treated NB4/ GFP-MAD cells, while JNKWT was ineffective, thus demonstrating that JNK is a critical mediator of ATRA-induced apoptosis of these cells. To analyse whether apoptosis of ATRA-treated NB4/ GFP-MAD cells was accompanied by increased production of ROS, cells were loaded with membranepermeant dihydroethidium (HE), which is oxidized to red fluorescent ethidium by superoxide anions. Subsequently, cells with increased red fluorescence were analysed by flow cytometry. As shown in Figure 6a and b, superoxide accumulation was observed in ATRA-treated NB4/GFP-MAD cells, with kinetics that paralleled those of cell death (Figure 4b ). In contrast, the ATRA-induced ROS accumulation was only moderate in NB4/GFP cells. Similarly to its effect on TNFa-induced ROS production (Kamata et al., 2005) , the oxygen radical scavenger butylated hydroxyanisol (BHA, 100 mM) decreased ROS accumulation in ATRAtreated NB4/GFP-MAD cells. Excess ROS production may result in oxidative damage, for which proteins are one of the major targets. We therefore compared the content of oxidized proteins after ATRA treatment of the two cell lines. As shown in Figure 6c , proteins with carbonyl groups, which are introduced in these molecules as a consequence of oxidation, were more abundant in ATRA-treated NB4/ GFP-MAD cells than in control cells or in similarly treated NB4/GFP cells. In accordance with its ROS scavenging effect, BHA inhibited protein oxidation.
NF-kB-mediated inhibition of ROS levels represses
To assess the role of ROS in ATRA-induced apoptosis of NB4/GFP-MAD cells, they were treated with BHA at day 3 of ATRA treatment, and the percentage of apoptotic cells was determined 2 and 3 days later. BHA strongly reduced apoptosis of NB4/ GFP-MAD cells, showing that after ATRA treatment oxidative stress is a crucial step in the sequence of reactions that lead to death of these cells (Figure 7a ). Scavenging of ROS with BHA also inhibited reduction of DCm and JNK activation as shown in Figure 7b and c, respectively. These results demonstrate that an early step of the death cascade consists in ROS accumulation which, in turn, activates JNK activity, and that the antiapoptotic effect of NF-kB results from its ability to control the intracellular ROS level.
Discussion
A complex and integrated network of intracellular signaling pathways determines whether a cell will either proliferate, differentiate, survive, or die. Pathological situations often result from perturbations of this network, and careful dissection of these pathways will help in the design of new targets for improved efficiency of therapeutic interventions. Among the main pathways that control cell fate are those that activate the NF-kB transcription factor. We here investigated the role of this transcription factor during the course of ATRA-induced differentiation of APL-derived NB4 cells. We report that inhibition of NF-kB activation does not impair the differentiation process, but resulted in a decreased viability of the differentiated cells.
NF-kB activates the transcription of several genes encoding for proteins capable of suppressing cell death (Kucharczak et al., 2003) . In this context, it has been reported that treatment of NB4 cells with ATRA resulted in increased expression of several NF-kBregulated mRNAs . However, in the present study, we could not detect any NF-kBdependent increase in expression of cIAP1, cIAP2, XIAP, and Bcl-xl at the protein level, suggesting that these proteins are most likely not the mediators of the antiapoptotic effect of NF-kB in ATRA-treated NB4 cells. Regulation of translation and stability of (Gebauer and Hentze, 2004) . In ATRA-treated NB4 cells, this may explain the discrepancy between expression of the antiapoptotic proteins encoding mRNAs and expression of the corresponding proteins. RNAse protection assays also revealed an increase in the expression of the A1/Bfl1 gene, encoding for an antiapoptotic protein of the Bcl2 family . The anti-A1/Bfl1 antibodies we used did not allow us to detect this protein either in control or in ATRA-treated cells. However, since A1/BEl1 À/À mice show accelerated neutrophil apoptosis (Hamasaki et al., 1998) , one cannot eliminate a possible role of this protein in the survival of ATRA-treated NB4 cells.
Recently, a novel mechanism for the protective effect of NF-kB against TNFa-induced apoptosis has been described, which implicates repression of JNK activation (De Smaele et al., 2001; Javelaud and Besanc¸on, 2001; Tang et al., 2001; Papa et al., 2004) . This kinase is predominantly activated by inflammatory cytokines, growth factors, and stress stimuli. Upon activation by phosphorylation on Tyr and Thr residues, JNK can translocate to the nucleus, where it activates several transcription factors, including c-jun, ATF2 and Elk-1, or phosphorylate non-nuclear substrates such as Bcl2 family members (Davis, 2000) . This allows JNK to contribute to diverse biological processes, including cell proliferation and cell death, and an obligatory role of this kinase in various stress-induced apoptosis models has clearly been demonstrated (Lin and Dibling, 2002) . Induction of prolonged JNK activation by various inducers was shown to result from intracellular ROS accumulation (Chen et al., 2003; Sakon et al., 2003) through direct activation of ASK1 (Matsuzawa et al., 2002) or through oxidative inactivation of endogenous JNK inhibitors, such as JNK phosphatases and glutathione S-transferase (Adler et al., 1999; Kamata et al., 2005) . In accordance with these observations and with the fact that mature human neutrophils can generate ROS (Clark, 1990) , we found that impairment of NF-kB activation resulted in increased ROS levels and JNK activation in ATRA-treated NB4 cells. Inhibition of JNK by the specific inhibitor SP600125 or by transfection of a dominant-negative mutant of JNK1 reduced the percentage of apoptotic cells, thus showing that JNK activation participates in the signalling to death. Inhibition of ROS accumulation by the antioxidant BHA abolished both JNK activation and apoptosis. These results demonstrate that oxidative stress is an initial event in the apoptotic cascade upstream of JNK activation. We therefore conclude that the antiapoptotic effect of NF-kB during the course of ATRA-induced differentiation of NB4 cells essentially results from the ability of this transcription factor to control the oxidative status of the cell and, consequently, JNK activity (Figure 7d) .
NF-kB has been reported to upregulate the expression of several antioxidant effectors, such as manganese superoxide dismutase, heme oxygenase, glutathione cysteine synthetase, glutathione, thioredoxin, and ferritin heavy chain (Iwanaga et al., 1998; Bernard et al., 2002; Brouard et al., 2002; Djavaheri-Mergny et al., 2004; Pham et al., 2004) . Inversely, negative control of expression of the p450 family CYP1B1 also participates in NF-kB antioxidant effect (Chen et al., 2003) . It will be interesting to elucidate the mechanism that is implicated in the repression of ROS accumulation in ATRAtreated NB4 cells by NF-kB. However, since an extensive regulation of protein expression occurs at the translation level during granulocytic differentiation (Grolleau et al., 1999; Gebauer and Hentze, 2004) , this study will require specific proteomic analysis. Aberrant NF-kB activity contributes to neoplastic clone survival and lower sensitivity to apoptosis in several hematologic malignancies (Turco et al., 2004) . The fact that we could obtain viable NB4 cells expressing a super repressor of NF-kB activation suggests that a constitutive NF-kB activity is not the essential cause of leukemic cell survival in APL. In contrast, our results demonstrate that activation of NFkB increases the viability of the differentiated cells. ATRA-induced differentiation on APL cells results in the activation of several leukocyte functions, including expression of adhesion molecules and secretion of cytokines. These events allow myeloid precursors and mature granulocytes to infiltrate several organs, and are believed to be involved in generation of the retinoic acid syndrome (RAS), which remains the major side effect of ATRA and can lead to fatal outcome (De Botton et al., 1998; Tallman et al., 2000; Larson and Tallman, 2003) . Until now, the best approach to treat patients with RAS is early identification of the symptoms and administration of dexamethasone (Larson and Tallman, 2003) . From our results, we conclude that the efficiency of this approach may be linked, at least partly, to the ability of this compound to inhibit NF-kB activation (Adcock, 2001) , and consequently to reduce the survival time of differentiated APL cells. We suggest that inclusion of specific inhibitors of NF-kB activity in combination therapies with ATRA may be helpful in reducing RAS incidence.
Materials and methods
Reagents
Recombinant human TNFa, TRAIL, and FasL were from Boehringer (Vienna, Austria), R&D Systems (Lille, France), and Alexis Biochemicals (Illkirch, France), respectively. MitoTracker Red (CMXRos) and HE were obtained from Molecular Probes (Eugene, USA). The JNK inhibitor SP 600125 was from Biomol (Plymouth Meeting, PA, USA). The calpain inhibitor PD150606 and its inactive analogue PD145305, the NBD (-DRQIKIWFQNRRMKWKK-), the IkB kinase inhibitor peptide (-AAVALLPAVLLALLAP-), and Bay 11-7082 were obtained from Calbiochem (San Diego, USA). ATRA and BHA were purchased from Sigma-Aldrich (St Quentin Fallavier, France).
Cells and retroviral infections
Construction of the NF-kB super repressor-encoding retroviral vector (Migr-eGFP-IkBaA32/36) and infection procedures have been described previously (Komura et al., 2005) . NB4 cells and derived transfected cells were grown in RPMI 1640 medium containing 10% decomplemented fetal calf serum.
Transfection of cells by electroporation
10
7 NB4/GFP-MAD cells growing in log phase were washed in serum-free medium and then resuspended in medium containing 6 mg of the empty pcDNA3 vector or the vector encoding for mutant JNKDN or JNKWT together with 4 mg of the pDsRED2 vector (BD Biosciences, Clontech, San Jose, CA, USA). Cells were then electroporated with 1500 mF and 200 V. The pcDNA vectors encoding wild-type JNK1 or dominantnegative mutant of JNK1 (Ala and Phe substituted at Thr183 and Tyr185, respectively) were described previously (Xia et al., 1995; Atfi et al., 1997) .
Gel shift assays
Nuclear extracts and EMSA were performed as described previously (Besanc¸on et al., 1998) . Briefly, the double-stranded consensus NF-kB probe: 5 0 -AGT TGA GGG GAC TTT CCC AGG C-3 0 ; -3 0 -TCA ACT CCC CTG AAA GGG TCC G-5 0 was end-labelled using (g 32 P)ATP and T4 polynucleotide kinase. Binding reactions were carried out in a 20 ml binding reaction mixture (10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.5 mM DTT, 10% glycerol, 0.2% Nonidet P-40), and 4 mg of poly(dI-dC)(dI-dC) containing 5 mg of nuclear proteins and 0.5 ng of the radiolabelled probe. Samples were incubated for 45 min on ice and fractionated by electrophoresis on a 6% non-denaturing polyacrylamide gel. Gels were run at 200 V for 3.5 h, dried and exposed to a Phosphorimager screen.
Cell differentiation, viability and apoptosis assays
Granulocytic maturation was evaluated by (1) examination of cellular morphology on cytospin specimen stained with MayGrunwald-Giemsa, (2) a histological NBT reduction assay performed as described previously (Lanotte et al., 1991) , and (3) analysis by direct immunofluorescence of changes in cell surface adhesion molecule CD11c expression. For this purpose, cells were incubated with the R-phycoerythrin (R-PE)-conjugated anti-CD11c antibody or the corresponding R-PE-conjugated isotype control (BD Biosciences), washed in PBS containing 0.1% bovine serum albumin, 0.01% sodium azide, fixed in 1% paraformaldehyde/PBS solution and analysed using a FACSCALIBUR (BD Biosciences) flow cytometer.
Cell viability was determined by the Trypan Blue dye exclusion method. Apoptosis was assessed by microscopic observation of morphological changes characteristic of apoptosis (i.e. condensation and fragmentation of nuclei) using staining with Hoechst 33258 fluorescent dye. A total of at least 300 nuclei were counted for each sample. Analysis of DNA laddering was carried out according to a previously described procedure (Besanc¸on et al., 1998) .
Variation of the mitochondrial membrane potential (DCm) was studied using the red fluorescent compound CMXRos. Cells were incubated with 100 nM CMXRos for 30 min at 371C before flow cytometry analysis.
Immunoblot analysis
Cellular extracts were prepared and Western blot analysis were performed as described previously (Javelaud et al., 2000) . The following antibodies were used: rabbit polyclonal antibodies against phospho-JNK(Thr183/Tyr185), IkBa/MAD3, JNK, cIAP1, cIAP2, A1/Bfl-1 (FL-175), A1/Bfl-1 (T-18) (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), Bcl-xl (BD Biosciences); monoclonal antibodies against phospho-IkBa(-Ser32/36) (New England Biolabs, Beverly, MA, USA), XIAP (Medical and Biological Laboratories Co., Ltd, Nagaya, Japan), caspase-9, clone 96-2-22 (Upstate, Lake Placid, USA). Anti-actin antibodies (ICN Biomedicals, Aurora, OH, USA) were used as a control for protein loading.
Flow cytometry analysis of death receptor expression
Surface TNFR1 levels were determined using the MABTNFR1-B1 antibody (BD Pharmigen) according to the manufacturer's instructions. Surface expression of Fas or TRAIL receptors DR4 and DR5 was analysed by incubating the cells with mouse anti-human Fas or DR4 and DR5 antibodies (Alexis), respectively, followed by biotinylated goat anti-mouse antibody and streptavidin phycoerythrin (BD Pharmigen).
Assay for intracellular ROS levels and detection of carbonylated proteins
To detect intracellular superoxide, cells were loaded for 30 min at 371C with the membrane-permeant HE (0.5 mM). Red ethidium (Eth) fluorescence was monitored by flow cytometry analysis with excitation at 488 nm and emission at 605 nm.
Protein oxidation was revealed using the Oxyblott kit (Intergen, New York, NY, USA). Briefly, 2,4-dinitrophenylhydrazine was added to whole-cell extracts in order to derivatize the carbonyl groups in the protein side chains to 2,4-dinitrophenylhydrazone (DNP), which were analysed by Western blotting with anti-DNP antibodies.
